Cargando…
Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
OBJECTIVE: The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients. METHODS: aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neuropsychiatric Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965658/ https://www.ncbi.nlm.nih.gov/pubmed/27482249 http://dx.doi.org/10.4306/pi.2016.13.4.458 |
_version_ | 1782445288332460032 |
---|---|
author | Woo, Young Sup Park, Joo Eon Kim, Do-Hoon Sohn, Inki Hwang, Tae-Yeon Park, Young-Min Jon, Duk-In Jeong, Jong-Hyun Bahk, Won-Myong |
author_facet | Woo, Young Sup Park, Joo Eon Kim, Do-Hoon Sohn, Inki Hwang, Tae-Yeon Park, Young-Min Jon, Duk-In Jeong, Jong-Hyun Bahk, Won-Myong |
author_sort | Woo, Young Sup |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients. METHODS: aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP were recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to their existing AAP regimen, which was maintained during the study period. Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) were investigated. RESULTS: The PANSS total score was significantly decreased at 12 weeks of blonanserin augmentation (-21.0±18.1, F=105.849, p<0.001). Moreover, 51.0% of participants experienced a response at week 12. Premature discontinuation of blonanserin occurred in 17 patients (17.0%); 4 of these patients dropped out due to adverse events. The patients who benefited the most from blonanserin were those with severe symptoms despite a treatment with a higher dose of AAP. CONCLUSION: Blonanserin augmentation could be an effective strategy for patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP. |
format | Online Article Text |
id | pubmed-4965658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Neuropsychiatric Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-49656582016-08-01 Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study Woo, Young Sup Park, Joo Eon Kim, Do-Hoon Sohn, Inki Hwang, Tae-Yeon Park, Young-Min Jon, Duk-In Jeong, Jong-Hyun Bahk, Won-Myong Psychiatry Investig Original Article OBJECTIVE: The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients. METHODS: aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP were recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to their existing AAP regimen, which was maintained during the study period. Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) were investigated. RESULTS: The PANSS total score was significantly decreased at 12 weeks of blonanserin augmentation (-21.0±18.1, F=105.849, p<0.001). Moreover, 51.0% of participants experienced a response at week 12. Premature discontinuation of blonanserin occurred in 17 patients (17.0%); 4 of these patients dropped out due to adverse events. The patients who benefited the most from blonanserin were those with severe symptoms despite a treatment with a higher dose of AAP. CONCLUSION: Blonanserin augmentation could be an effective strategy for patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP. Korean Neuropsychiatric Association 2016-07 2016-07-25 /pmc/articles/PMC4965658/ /pubmed/27482249 http://dx.doi.org/10.4306/pi.2016.13.4.458 Text en Copyright © 2016 Korean Neuropsychiatric Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Woo, Young Sup Park, Joo Eon Kim, Do-Hoon Sohn, Inki Hwang, Tae-Yeon Park, Young-Min Jon, Duk-In Jeong, Jong-Hyun Bahk, Won-Myong Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title | Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title_full | Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title_fullStr | Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title_full_unstemmed | Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title_short | Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study |
title_sort | blonanserin augmentation of atypical antipsychotics in patients with schizophrenia-who benefits from blonanserin augmentation?: an open-label, prospective, multicenter study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965658/ https://www.ncbi.nlm.nih.gov/pubmed/27482249 http://dx.doi.org/10.4306/pi.2016.13.4.458 |
work_keys_str_mv | AT wooyoungsup blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT parkjooeon blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT kimdohoon blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT sohninki blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT hwangtaeyeon blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT parkyoungmin blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT jondukin blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT jeongjonghyun blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy AT bahkwonmyong blonanserinaugmentationofatypicalantipsychoticsinpatientswithschizophreniawhobenefitsfromblonanserinaugmentationanopenlabelprospectivemulticenterstudy |